Our look is new. Our purpose is the same. Learn more about our brand evolution.
Here’s some encouraging news about Fulcrum Therapeutics. The Cambridge, Massachusetts-based biotech that is developing a drug to treat Facioscapulohumeral muscular dystrophy has announced it has closed $80 million in series […]
Today, The FSH Society, the world’s largest research-focused patient organization for facioscapulohumeral muscular dystrophy (FSHD), announced the launch of its national chapter development program to provide the opportunity to fund more […]
When one path ended, a new one opened up by Nelson Dronet, Sulphur, Louisiana I would like to take a moment to share my story in the hope that it reaches […]
Researchers at the University of Texas Southwestern Medical Center in Dallas announced that they have made a significant advance in demonstrating the possibility of using CRISPR gene editing technology as […]
Reposted from Facio Therapies, Leiden, The Netherlands – August 30, 2018 Facio Therapies announced today that it has selected a second series of potential candidates for FSHD drug development. This […]
